Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Hospitalization 100%
• Disease Prevention 100%
• Atorvastatin 100%
• Disease Progression 100%
• Liver Cirrhosis 100%
• Liver 50%
• Cirrhosis 50%
• Systemic Inflammation 50%
• EudraCT 50%
• Clinical Outcomes 25%
• Denmark 25%
• Inflammation 25%
• Placebo-controlled Trial 25%
• Metabolic Dysfunction 25%
• Beneficial Effects 25%
• Randomized Clinical Trial 25%
• Cellular Dysfunction 25%
• Safety Profile 25%
• Consolidated Standards of Reporting Trials (CONSORT) 25%
• Clinical Management 25%
• Protein Function 25%
• Chronic Liver Disease 25%
• Double-blind Trial 25%
• Ethics Committees 25%
• Clinical Endpoints 25%
• Capital Region 25%
• Hepatic Stellate Cells 25%
• Data Protection 25%
• Protection Agency 25%
• Patients with Liver Disease 25%
• Causal Treatment Effect 25%
• 2-year Survival 25%
• Scientific Ethics 25%
• Evidence-based Support 25%
• Genomic Function 25%

Medicine and Dentistry

• Placebo 100%
• Atorvastatin 100%
• Liver Cirrhosis 100%
• Disease Exacerbation 100%
• Inflammation 50%
• Liver Disease 16%
• Clinical Management 16%
• Chronic Liver Disease 16%
• Clinical Endpoint 16%
• Hepatic Stellate Cell 16%
• Randomized Clinical Trials 16%
• Genetics 16%
• Protein Function 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Atorvastatin 100%
• Disease Exacerbation 100%
• Liver Cirrhosis 100%
• Inflammation 50%
• Randomized Clinical Trial 16%
• Liver Disease 16%
• Chronic Liver Disease 16%